Region Oerebro Laen

The University Hospital Örebro Hematology Clinic conducts extensive research on blood‑related cancers, focusing on diseases such as acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and mantle‑cell lymphoma. Trials aim to test innovative targeted agents, immunotherapy combinations, and maintenance strategies to improve survival and quality of life.

• Evaluation of novel BTK inhibitors combined with standard chemotherapy
• Biomarker‑driven de‑escalation of therapy in early‑stage breast cancer
• Maintenance rituximab versus observation in ANCA‑associated vasculitis
• Adding capecitabine to carboplatin‑based regimens for triple‑negative breast cancer
• Comparative effectiveness of CAR‑T versus standard salvage therapy in relapsed myeloma

With 78 investigators and 95 active studies, the site supports rapid patient enrollment and multidisciplinary collaboration.

Research in this area addresses cardiovascular diseases and metabolic disorders, including coronary artery disease, heart failure with preserved ejection fraction, atrial fibrillation, and type 2 diabetes. The primary goal is to evaluate new antiplatelet regimens, SGLT2 inhibitors, and anticoagulation alternatives to reduce events such as myocardial infarction, stroke, and hospitalization.

• Dual antiplatelet therapy with ticagrelor after coronary artery bypass grafting
• SGLT2 inhibitor dapagliflozin for postoperative atrial fibrillation prevention
• Metformin impact on growth of small abdominal aortic aneurysms
• AbeLacimab versus placebo for stroke risk reduction in high‑risk atrial fibrillation
• Spironolactone addition to standard care in heart failure with preserved ejection fraction

These cardiovascular trials aim to refine therapeutic guidelines and enhance long‑term outcomes for Swedish patients.

The department’s respiratory portfolio includes chronic obstructive pulmonary disease, asthma, and immune‑mediated skin conditions such as atopic dermatitis and hidradenitis suppurativa. Studies test biologic agents, inhaled combination therapies, and vaccine strategies to improve lung function, reduce exacerbations, and control inflammation.

• Triple inhaled therapy (BGF) versus dual bronchodilator in severe COPD
• IL‑6R blockade with tocilizumab for immune‑checkpoint inhibitor‑induced arthritis
• Amlitelimab safety and efficacy in moderate‑to‑severe atopic dermatitis
• AZD4604 evaluation in uncontrolled moderate‑to‑severe asthma
• ExPEC9V vaccine to prevent invasive E. coli disease in older adults

By integrating immunology and pulmonology expertise, the trials seek to deliver personalized treatment pathways for chronic respiratory patients.

Investigations target digestive system diseases and related immune disorders, covering inflammatory bowel disease (Crohn’s and ulcerative colitis), primary sclerosing cholangitis, and colorectal cancers with specific genetic alterations. The purpose is to assess novel biologic combos, adjuvant therapies, and biomarker‑guided treatment intensification.

• Combination of guselkumab and golimumab for moderate‑to‑severe Crohn’s disease
• Luteal phase support with vaginal progesterone to improve live birth after IVF
• Simvastatin for disease modification in primary sclerosing cholangitis
• Early outpatient induction versus inpatient induction for labor

These studies aim to reduce disease activity, prevent cancer recurrence, and improve quality of life for gastrointestinal patients.

The site explores disorders of the nervous system and mental health, including Alzheimer’s disease, major depressive disorder, schizophrenia spectrum disorders, and traumatic brain injury. Trials focus on neuroprotective agents, novel antidepressants, and rehabilitation strategies to enhance cognition and functional recovery.

• Cognitive outcomes in early‑stage Alzheimer’s disease with disease‑modifying therapy
• Efficacy of a new serotonin‑modulating agent for major depression
• Early intervention protocol for sub‑acute moderate to severe traumatic brain injury
• Corticosteroid versus placebo for acute facial nerve palsy recovery
• Biomarker‑guided de‑escalation of antipsychotic medication in schizophrenia

Multidisciplinary collaboration with neurology, psychiatry, and rehabilitation services drives these innovative approaches.

Research in this field addresses bacterial infections and surgical complications, focusing on Staphylococcus aureus bacteremia, prosthetic joint infection, and urinary tract infections. Clinical trials evaluate vaccine candidates, antibiotic‑impregnated bone grafts, and peri‑operative antimicrobial strategies to reduce infection rates and improve surgical outcomes.

• ExPEC9V vaccine to prevent invasive E. coli disease in adults with prior UTI
• Antibiotic‑impregnated bone graft versus placebo in hip arthroplasty infection prevention
• Comparison of benzylpenicillin and cloxacillin for penicillin‑susceptible Staphylococcus aureus bacteremia
• Intravenous glutamate infusion to prevent acute kidney injury after coronary bypass surgery
• Metformin transfer into breast milk and infant plasma safety study

The integration of infectious disease expertise with surgical practice enhances patient safety and postoperative recovery.